Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer/Ligand’s Osteoporosis Drug Fablyn Gets Advisory Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Lasofoxifene beats out Wyeth’s Viviant for first advisory committee review of the competing next-generation SERMs.

You may also be interested in...

Wyeth’s Viviant “Approvable” For Osteoporosis

Analysis sought for treatment indication is similar to what FDA requested for prevention setting.

Pfizer Files Lasofoxifene NDA For Treatment Of Osteoporosis

Selective estrogen receptor modulator now is called Fablyn rather than Oporia, a name under which it received two “not approvable” letters.

Wyeth’s Viviant “Approvable” For Prevention Of Postmenopausal Osteoporosis

Firm continues to plan an additional submission this year for an osteoporosis treatment claim.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts